- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05482568
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
October 12, 2023 updated by: Jiangsu HengRui Medicine Co., Ltd.
Phase IB/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer With HER2
This study was an open, multicenter, dose-increasing/investigational Phase IB/II clinical trial to evaluate the efficacy of SHR-A1811 in combination with other antitumor therapies in subjects with advanced non-small cell lung cancer with HER2 .
It can be divided into two parts, Part A is the dose escalation and efficacy exploration study of SHR-A1811 combined with Pyrotinib, and Part B is the dose escalation and efficacy exploration study of SHR-A1811 combined with SHR-1316.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
324
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Suqiang Yu
- Phone Number: +0518-82342973
- Email: suqiang.yu@hengrui.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Recruiting
- Shanghai Chest Hospital
-
Principal Investigator:
- Shun Lu
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Recruiting
- Zhejiang Cancer Hospital
-
Principal Investigator:
- Zhengbo Song
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Ability to give informed consent, signed and dated IRB/EC approved informed consent, willing and able to comply with treatment planning visits, tests and other procedural requirements
- When signing the informed consent, the age is 18-75 years old (including both ends), and there is no gender limitation
- The ECOG score is 0 or 1
- The expected survival is ≥12 weeks
- Subjects with advanced or metastatic non-small cell lung cancer
- Formalin fixed, paraffin-embedded tumor tissue blocks or sections of unstained tumor specimens are provided
- Subjects who have failed prior standard care or are intolerant to standard care
- There is at least one measurable lesion
- Vital organs are functioning well
- Heart function is good
- Agree to birth control
Exclusion Criteria:
- There are untreated or active central nervous system (CNS) tumor metastases
- Pleural, ascites, or pericardial effusion requiring intervention occurred within 7 days prior to initial administration
- Systemic antitumor therapy was performed 4 weeks prior to study initiation
- Prior treatment with antibody-conjugated drugs
- Received >30 Gy chest radiation within 6 months prior to initial administration
- Palliative radiotherapy was completed within 7 days prior to initial administration
- Failure to recover from toxicity and/or complications of previous interventions to nCI-CTCAE ≤1
- The half-life of CYP3A4 suppressor, moderate inhibitor or strong inducer or moderate inducer is less than 3 or less than 14 days from the date of first drug use, and the shorter is selected
- Received systemic immunosuppressant therapy within 14 days prior to the first study
- Subjects with known or suspected interstitial pneumonia
- In the first study, failure to swallow, chronic diarrhea, gastroenteritis, intestinal obstruction, gastrointestinal perforation, postgastrectomy, or colitis, or other medical conditions or special conditions affecting drug administration and absorption occurred within 28 days prior to administration
- Presence of any active, known or suspected autoimmune disease
- Have poorly controlled or severe cardiovascular disease
- Previous or concurrent malignancy
- Subjects who developed a severe infection within 28 days prior to the first dose
- Active hepatitis B
- There were active tuberculosis patients within 1 year before enrollment
- There is a history of immunodeficiency
- Live attenuated vaccine was administered within 28 days prior to initial study administration or is expected to be administered during study treatment
- Subjects who are participating in another clinical study or who have had their first dose less than 4 weeks since the end of the previous clinical study (last dose) or 5 half-lives of the study drug, whichever is shorter
- Major surgery other than diagnosis or biopsy was performed within 28 days prior to initial administration
- People who are known to be allergic to sir-A1811, pyrrolitinib, or any of the components of SIR-1316
- History of severe allergic reactions to other monoclonal antibody/fusion protein drugs
- Female subjects who are pregnant, breast-feeding, or planning to become pregnant during the study
- Uncontrolled mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse and detention
- Any other conditions that, in the investigator's judgment, may increase the risk of study participation, interfere with study results, or make study participation unsuitable
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SHR-A1811 combined with Pyrotinib/SHR-A1811 combined with SHR-1316
|
Drug: SHR-A1811 & Pyrotinib SHR-A1811: intravenous Pyrotinib:oral Drug: SHR-A1811 & SHR-1316 SHR-A1811: intravenous SHR-1316: intravenous |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
DLT(Phase I (dose exploration phase) main study endpoint)
Time Frame: 21 days after the first administration of each subject
|
21 days after the first administration of each subject
|
AE(Phase I (dose exploration phase) main study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Incidence and severity of serious adverse events (SAE)(Phase I (dose exploration phase) main study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Objective response rate(The main end points of the second stage (efficacy expansion stage))
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Toxin binding antibody to shr-a1811(Phase I secondary endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Total antibody to shr-a1811(Phase I secondary endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Plasma concentration of free toxin shr169265(Phase I secondary endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Plasma concentration of pyrroltinib(Phase I secondary endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Plasma concentration of SHR-1316(Phase I secondary endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Anti shr-a1811 antibody positive(Phase I secondary endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
The positive status of neutralizing antibody against shr-a1811(Phase I secondary endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Anti shr-1316 antibody positive(Phase I secondary endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
The positive status of neutralizing antibody against shr-1316(Phase I secondary endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Objective Response Rate(Phase I secondary endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Duration of response(Phase I secondary endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Progression Free Survival(Phase I secondary endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
AE(Phase II secondary study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Incidence and severity of serious adverse events (SAE)(Phase II secondary study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Toxin binding antibody to shr-a1811(Phase II secondary study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Total antibody to shr-a1811(Phase II secondary study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Plasma concentration of free toxin shr169265(Phase II secondary study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Plasma concentration of pyrroltinib(Phase II secondary study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Plasma concentration of SHR-1316(Phase II secondary study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Anti shr-a1811 antibody positive(Phase II secondary study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
The positive status of neutralizing antibody against shr-a1811(Phase II secondary study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Anti shr-1316 antibody positive(Phase II secondary study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
The positive status of neutralizing antibody against shr-1316(Phase II secondary study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Duration of response(Phase II secondary study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Progression Free Survival(Phase II secondary study endpoint)
Time Frame: Two years after the last subject was enrolled in the group
|
Two years after the last subject was enrolled in the group
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 15, 2022
Primary Completion (Estimated)
November 30, 2023
Study Completion (Estimated)
December 30, 2024
Study Registration Dates
First Submitted
July 26, 2022
First Submitted That Met QC Criteria
July 29, 2022
First Posted (Actual)
August 1, 2022
Study Record Updates
Last Update Posted (Actual)
October 16, 2023
Last Update Submitted That Met QC Criteria
October 12, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR-A1811-II-203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Non-small Cell Lung Cancer
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerFrance, Korea, Republic of, United Kingdom, Spain
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerBelgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerUnited States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
Gradalis, Inc.WithdrawnLung Neoplasms | Advanced Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung CancerUnited States
-
Cancer Research UKBicycle TherapeuticsCompletedNon-Small Cell Lung Cancer | Advanced Solid Tumours | Oesophageal Cancer | Non-Small Cell Lung SarcomaUnited Kingdom
-
Mirati Therapeutics Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung CancerUnited States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyCompletedNon-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung CancerUnited States
-
LianBio LLCRecruitingAdvanced Solid Tumor | Advanced or Metastatic Non-small Cell Lung CancerChina
Clinical Trials on SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingHER2-expressing Advanced Solid TumorsChina
-
Henan Cancer HospitalRecruitingHER2 Low Breast CarcinomaChina
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.RecruitingHER2-positive Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingGastric Cancer | Colorectal CancerChina
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingHER2 Expression / Amplification in Patients With Biliary Tract CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina